NCT07486102
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 21 words Show 5 more changesShow less
- Trial completed
- Final enrollment: 34 participants (planned 44)
- Primary completion date changed from estimate of Feb 26, 2027 to Oct 30, 2026
- Study completion date changed from estimate of Feb 27, 2027 to Oct 31, 2026
- Site details revised
- Notable Recruitment opened
- Start date changed from estimate of May 4, 2026 to May 1, 2026
- Site details revised
- Minor Start date: Apr 15, 2026 to May 4, 2026v4
- Notable Eligibility criteria expanded, about 65 wordsv3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Timeframe: Up to 8 days
Maximum measured concentration of the analyte in plasma (Cmax)
Timeframe: Up to 8 days
Secondary (1)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Arms and interventions
Participants with mild hepatic impairment (Child-Pugh A)Experimental
Participants with moderate hepatic impairment (Child-Pugh B)Experimental
Participants with severe hepatic impairment (Child-Pugh C)Experimental
Participants with normal hepatic functionExperimental
Drugs: BI 3000202
Sites
1 site in 1 country
- American Research Corporation at the Texas Liver InstituteSan Antonio, Texas, United States